CJC-1295 vs MK-677
Head-to-head comparison of CJC-1295 and MK-677 for research applications. Both peptides are studied for Anti-Aging and Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Mk 677 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | MK-677 binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus, mimicking the hunger hormone ghrelin. |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / Not approved for human use | Multiple Phase II trials completed. Not FDA-approved. Investigational. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain; Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics |
| Route | Subcutaneous | Oral (capsule or liquid) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 10–25 mg/day orally |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~528.7 g/mol (624.8 as mesylate salt) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~4–6 hours (plasma); functional activity ~24 hours |
Overview
CJC-1295 and MK-677 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
CJC-1295 DAC 5mg
5mg
MK-677 — Mechanism & Evidence
MK-677 (Ibutamoren) is a potent, long-acting, orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release without injections. Unlike injectable GH peptides such as GHRP-6 or Ipamorelin, MK-677 can be taken orally and maintains elevated GH and IGF-1 levels for up to 24 hours. It has been studied in several human clinical trials for GH deficiency, muscle wasting, bone density, and sleep quality, but is not FDA-approved for any indication.
Key claims: Increases growth hormone and IGF-1 levels; Improves sleep quality; Increases lean body mass.
Shared Research Applications
Both peptides are studied for: Anti-Aging, Body Composition.
CJC-1295 is also researched for: no additional unique applications.
MK-677 is also researched for: Sleep.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
MK-677: Common: increased appetite (ghrelin agonism), water retention/mild edema, transient muscle pain Metabolic: may elevate fasting blood glucose and reduce insulin sensitivity (dose-dependent); important for diabetics and pre-diabetics Fatigue and lethargy reported by some users
Shop Research Peptides
CJC-1295 DAC 5mg
5mg
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
CJC-1295 vs Sermorelin: Comparing Growth Hormone-Releasing Peptides
Compare CJC-1295 vs Sermorelin for growth hormone release. Analyze mechanisms, preclinical data, and research limitations for these GHRH analogs.
CJC-1295 and Weight Loss: A Research Overview
Explore CJC-1295 research for weight loss: mechanisms, GH release, metabolism effects, and comparison with DAC variants.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe